Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page
- Check3 days agoChange DetectedA new page revision (v3.6.2) was added, replacing the previous version (v3.6.0); this appears to be a deployment or formatting update rather than a substantive change to the study details.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now indicates recruitment has closed with 'No longer looking for participants' and adds help sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. It also updates the revision tag to v3.6.0 and standardizes the label from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.4%

- Check24 days agoChange DetectedA new page revision tag v3.5.5 was added, replacing the previous v3.5.4 tag. This indicates a minor update to the page record rather than a change to study content or functionality.SummaryDifference0.1%

- Check46 days agoChange DetectedA new site revision v3.5.4 was added, replacing the previous revision v3.5.3. This reflects a routine platform update without changes to study information.SummaryDifference0.1%

- Check53 days agoChange DetectedAdds a Results and Publications section with post-study outcomes and citations for the CUPem trial, including major publications; also removes earlier narrative summaries of efficacy and RECIST-based outcomes.SummaryDifference6%

- Check67 days agoChange DetectedThe page’s footer “Revision” label has been updated from v3.5.2 to v3.5.3, indicating a minor site/content system revision rather than a change to the clinical trial details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.